Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTANSC1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 4	APR 07	STN is raising the limits on saved answers
NEWS 5	APR 24	CA/CAplus now has more comprehensive patent assignee information
NEWS 6	APR 26	USPATFULL and USPAT2 enhanced with patent assignment/reassignment information
NEWS 7	APR 28	CAS patent authority coverage expanded
NEWS 8	APR 28	ENCOMPLIT/ENCOMPLIT2 search fields enhanced
NEWS 9	APR 28	Limits doubled for structure searching in CAS REGISTRY
NEWS 10	MAY 08	STN Express, Version 8.4, now available
NEWS 11	MAY 11	STN on the Web enhanced
NEWS 12	MAY 11	BEILSTEIN substance information now available on STN Easy
NEWS 13	MAY 14	DGENE, PCTGEN and USGENE enhanced with increased limits for exact sequence match searches and introduction of free HIT display format
NEWS 14	MAY 15	INPADOCDB and INPAFAMDB enhanced with Chinese legal status data
NEWS 15	MAY 28	CAS databases on STN enhanced with NANO super role in records back to 1992
NEWS 16	JUN 01	CAS REGISTRY Source of Registration (SR) searching enhanced on STN
NEWS 17	JUN 26	NUTRACEUT and PHARMAML no longer updated
NEWS 18	JUN 29	IMSCOPROFILE now reloaded monthly
NEWS 19	JUN 29	EPFULL adds Simultaneous Left and Right Truncation (SLART) to AB, MCLM, and TI fields
NEWS 20	JUL 09	PATDPAFULL adds Simultaneous Left and Right Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 21	JUL 14	USGENE enhances coverage of patent sequence location (PSL) data
NEWS 22	JUL 27	CA/CAplus enhanced with new citing references
NEWS 23	JUL 16	GBFULL adds patent backfile data to 1855
NEWS 24	JUL 21	USGENE adds bibliographic and sequence information
NEWS 25	JUL 28	EPFULL adds first-page images and applicant-cited references
NEWS 26	JUL 28	INPADOCDB and INPAFAMDB add Russian legal status data

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

```
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:38:03 ON 04 AUG 2009

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.22       0.22

FILE 'REGISTRY' ENTERED AT 10:38:33 ON 04 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 AUG 2009  HIGHEST RN 1171815-79-4
DICTIONARY FILE UPDATES:   2 AUG 2009  HIGHEST RN 1171815-79-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10562296A.str
```



```
chain nodes :
1  2  3  4  5  6
chain bonds :
1-2  1-5  2-3  4-5  5-6
exact/norm bonds :
1-2  1-5  2-3  4-5  5-6


Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s sss sam l1
SAMPLE SEARCH INITIATED 10:38:58 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     3266 TO ITERATE

 61.2% PROCESSED     2000 ITERATIONS                                50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        61893 TO    68747
PROJECTED ANSWERS:           55949 TO    62475

L2           50 SEA SSS SAM L1

=> d scan

L2   50 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   INDEX NAME NOT YET ASSIGNED
MF   C17 H18 Cl N9 O8 S

Double bond geometry as shown.
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C19 H27 N9 O8

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s sss full l1
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 185.40 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 10:40:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 65502 TO ITERATE

100.0% PROCESSED 65502 ITERATIONS 60043 ANSWERS
SEARCH TIME: 00.00.03

L3 60043 SEA SSS FUL L1

=> save l3 acylguanidine/a
ACYLGUANIDINE/A IS NOT A VALID SAVED NAME

```
Enter the name you wish to use for the saved query,
answer set, or L-number list.  The name must:
  1. Begin with a letter,
  2. Have 1-12 characters,
  3. Contain only letters (A-Z) and numbers (0-9),
  4. End with /Q for a query (search profile,
     structure, or screen set), /A for an answer
     set, or /L for an L-number list.
  5. Not already be in use as a saved name,
  6. Not be END, SAV, SAVE, SAVED
  7. Not have the form of an L-number (Lnnn).
ENTER NAME OR (END):end

=> save l3 acylguanidin/a
ANSWER SET L3 HAS BEEN SAVED AS 'ACYLGUANIDIN/A'

=> fil caplus
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                187.80     188.02

FILE 'CAPLUS' ENTERED AT 10:41:42 ON 04 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 4 Aug 2009  VOL 151 ISS 6
FILE LAST UPDATED: 3 Aug 2009  (20090803/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information.  This enhancement may impact record import into
database management software.  For additional information, refer
to NEWS 22.

=> e us2005-562296/apps
E1            1     US2005-562293/AP
```

```
E2            1     US2005-562295/AP
E3            1 --> US2005-562296/AP
E4            0     US2005-562296/PRN
E5            1     US2005-562297/AP
E6            1     US2005-562298/AP
E7            1     US2005-562307/AP
E8            2     US2005-562311/AP
E9            1     US2005-562320/AP
E10           1     US2005-562322/AP
E11           1     US2005-562328/AP
E12           1     US2005-56233/AP

=> s e3
L4            1 US2005-562296/AP

=> sel rn l4
E1 THROUGH E149 ASSIGNED

=> fil reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.34     191.36

FILE 'REGISTRY' ENTERED AT 10:43:11 ON 04 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 AUG 2009  HIGHEST RN 1171815-79-4
DICTIONARY FILE UPDATES:   2 AUG 2009  HIGHEST RN 1171815-79-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s e1-e149
             1 111-49-9/BI
               (111-49-9/RN)
               (92660-58-7/RN)
             1 96861-65-3/BI
               (96861-65-3/RN)
             1 98-80-6/BI
               (98-80-6/RN)
L5         149 (111-49-9/BI OR 113-00-8/BI OR 1151-30-0/BI OR 1152-29-0/BI OR
               1154-25-2/BI OR 1161-94-0/BI OR 1166-01-4/BI OR 127105-63-9/BI
               OR 140-10-3/BI OR 1428-95-1/BI OR 1458-18-0/BI OR 147-85-3/BI
```

```
=> s l5 and l3
L6          118 L5 AND L3

=> fil caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       1.92     193.28

FILE 'CAPLUS' ENTERED AT 10:45:38 ON 04 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)
```

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

```
FILE COVERS 1907 - 4 Aug 2009  VOL 151 ISS 6
FILE LAST UPDATED: 3 Aug 2009  (20090803/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Jun 2009

CAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family
of databases have been updated to include new citing references
information.  This enhancement may impact record import into
database management software.  For additional information, refer
to NEWS 22.

=> s l6
L7          835 L6

=> s l7 and (ay<2005 or py<2005 or pry<2005)
       5133306 AY<2005
      25141203 PY<2005
       4610748 PRY<2005
L8          701 L7 AND (AY<2005 OR PY<2005 OR PRY<2005)

=> s l8 and antiviral
          75206 ANTIVIRAL
           1500 ANTIVIRALS
          75517 ANTIVIRAL
                (ANTIVIRAL OR ANTIVIRALS)
```

L9 8 L8 AND ANTIVIRAL

=> d ibib abs hitstr 1-8
THE ESTIMATED COST FOR THIS REQUEST IS 45.12 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:1016569 CAPLUS Full-text
DOCUMENT NUMBER: 148:503081
TITLE: Novel drug delivery system
INVENTOR(S): Nadkarni, Sunil Sadanand; Vaya, Navin; Karan, Rajesh Singh; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): Torrent Pharmaceuticals Limited, India
SOURCE: Indian Pat. Appl., 80pp., Addn. of Indian Appl. No. 2004MU198.
CODEN: INXXBQ
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
IN 2005MU01012	A	20070831	IN 2005-MU1012	20050826 <--
PRIORITY APPLN. INFO.:			IN 2004-MU198 A0	20040220 <--

AB A novel modified release dosage form comprising of a high solubility active ingredient, which utilizes dual retard technique to effectively reduce the quantity of release controlling agents. Present invention can optionally comprise addnl. another active ingredient as an immediate release form or modified release form. Present invention also relates to a process for preparing the said formulation.

IT 2016-88-8, Amiloride Hydrochloride
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)
RN 2016-88-8 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride (1:1) (CA INDEX NAME)



IT 60398-23-4, Iodoamiloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel drug delivery system)
RN 60398-23-4 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-iodo- (CA INDEX NAME)



L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:100738 CAPLUS Full-text
DOCUMENT NUMBER: 144:198849
TITLE: Novel dosage form comprising modified-release and immediate-release active ingredients
INVENTOR(S): Vaya, Navin; Karan, Rajesh Singh; Sadanand, Sunil; Gupta, Vinod Kumar
PATENT ASSIGNEE(S): India
SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 630,446.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20060024365	A1	20060202	US 2005-134633		20050519	<--
IN 2002MU00697	A	20040529	IN 2002-MU697		20020805	<--
IN 193042	A1	20040626				
IN 2002MU00699	A	20040529	IN 2002-MU699		20020805	<--
IN 2003MU00080	A	20050204	IN 2003-MU80		20030122	<--
IN 2003MU00082	A	20050204	IN 2003-MU82		20030122	<--
US 20040096499	A1	20040520	US 2003-630446		20030729	<--
PRIORITY APPLN. INFO.:			IN 2002-MU697	A	20020805	<--
			IN 2002-MU699	A	20020805	<--
			IN 2003-MU80	A	20030122	<--
			IN 2003-MU82	A	20030122	<--
			US 2003-630446	A2	20030729	<--

AB A dosage form comprising of a high dose, high solubility active ingredient as modified release and a low dose active ingredient as immediate release where the weight ratio of immediate release active ingredient and modified release active ingredient is from 1:10 to 1:15000 and the weight of modified release active ingredient per unit is from 500 mg to 1500 mg; a process for preparing the dosage form. Tablets containing 10 mg sodium pravastatin and 1000 mg niacin were prepared The release of sodium pravastatin after 24 h was 67.7%, and the release of niacin after 1 h was 84.1%.

IT 60398-23-4, Iodoamiloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel dosage form comprising modified-release and immediate-release active ingredients)

RN 60398-23-4 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-iodo- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:259835 CAPLUS Full-text
DOCUMENT NUMBER: 142:291365
TITLE: Inhibition of inward sodium currents in cancer
INVENTOR(S): Benos, Dale J.; Bubien, James K.; Gillespie, G. Yancey
PATENT ASSIGNEE(S): The Uab Research Foundation, USA
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005025518	A2	20050324	WO 2004-US29970	20040913 <--
WO 2005025518	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2538754	A1	20050324	CA 2004-2538754	20040913 <--
EP 1667735	A2	20060614	EP 2004-783981	20040913 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20070092444	A1	20070426	US 2006-571302	20060817 <--
PRIORITY APPLN. INFO.:			US 2003-502034P P	20030911 <--
			WO 2004-US29970 W	20040913 <--

AB Described is a constitutive inward Na+ currents found in a variety of human cancers. The constitutive inward Na+ current plays a role in increased cellular proliferation, cellular migration and volume regulation. The inward current is mediated, at least in part, by AISC- containing Na+ channels. In addition, an inhibitor of the inward current, the PcTX1 peptide, is described. Also provided are methods for screening compds. to inhibit the inward Na+ current, methods for screening for tumors expressing the inward Na+ current and methods for treating tumors expressing the inward Na+ current.

IT 2898-76-2, Benzamil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of inward sodium currents in cancer)
RN 2898-76-2 CAPLUS

CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-
[imino[(phenylmethyl)amino]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1156423 CAPLUS Full-text
DOCUMENT NUMBER: 142:86608
TITLE: Antiviral acylguanidine compounds, and their therapeutic use
INVENTOR(S): Gage, Peter William; Ewart, Gary Dinneen; Wilson, Lauren Elizabeth; Best, Wayne; Premkumar, Anita
PATENT ASSIGNEE(S): Biotron Limited, Australia
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112687	A2	20041229	WO 2004-AU866	20040626 <--
WO 2004112687	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
AU 2004248859	A1	20041229	AU 2004-248859	20040626 <--
CA 2529949	A1	20041229	CA 2004-2529949	20040626 <--
EP 1646371	A2	20060419	EP 2004-737487	20040626 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011900	A	20060919	BR 2004-11900	20040626 <--
JP 2007508234	T	20070405	JP 2006-515560	20040626 <--
ZA 2006000650	A	20070530	ZA 2006-650	20040626 <--
NZ 544671	A	20090228	NZ 2004-544671	20040626 <--
US 20070099968	A1	20070503	US 2005-562296	20051222 <--
IN 2006KN00159	A	20070727	IN 2006-KN159	20060120 <--
CN 101111475	A	20080123	CN 2004-80024097	20060222 <--
PRIORITY APPLN. INFO.:			AU 2003-903251 A	20030626 <--
			AU 2003-903850 A	20030725 <--

AU 2003-904692	A	20030829	<--
AU 2004-902902	A	20040531	<--
WO 2004-AU866	W	20040626	<--

OTHER SOURCE(S): MARPAT 142:86608

AB The invention discloses acylguanidine compds. having antiviral activity, as well as methods using these compds. to treat viral infections. Preparation of e.g. cinnamoylguanidine is included.

IT 216483-92-0, BODIPY FL-amiloride
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BODIPY FL-amiloride; antiviral acylguanidine compds. and therapeutic use)

RN 216483-92-0 CAPLUS

CN Boron, [3,5-diamino-6-chloro-N-[[[4-[[3-[5-[(3,5-dimethyl-2H-pyrrol-2-ylidene-κN)methyl]-1H-pyrrol-2-yl-κN]-1-oxopropyl]amino]butyl]amino]iminomethyl]pyrazinecarboxamidato]difluoro-, monohydrochloride, (T-4)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



IT 815585-07-0P 815585-08-1P 815585-09-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(antiviral acylguanidine compds. and therapeutic use)

RN 815585-07-0 CAPLUS

CN 2-Propenamide, N-(aminoiminomethyl)-3-phenyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-08-1 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-phenyl- (CA INDEX NAME)



RN 815585-09-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-5-(hexahydro-1H-azepin-1-yl)-6-phenyl- (CA INDEX NAME)



IT 1152-29-0 1154-25-2, EIPA 1161-94-0
1166-01-4, 3',4'-Dichlorobenzamil 1428-95-1,
5-(N,N-Hexamethylene)amiloride 2016-88-8, Amiloride
hydrochloride 2038-35-9, Phenamil 2088-58-6,
2',4'-DichloroBenzamil hydrochloride 2898-76-2, Benzamil
3166-00-5, Benzoylguanidine 27182-48-5
41266-22-2, (Phenylacetyl)guanidine 60398-23-4,
6-Iodoamiloride 90689-42-2, 2',4'-Dichlorobenzamil
92660-58-7 96861-65-3, MIA 127105-63-9,
5-(N-Methyl-N-guanidinocarbonylmethyl)amiloride 161804-20-2,
Benzamil hydrochloride 183271-12-7 188754-46-3
196190-73-5 196190-77-9 230639-31-3
265322-51-8 279241-29-1 741654-11-5
747394-28-1 749833-31-6 756794-68-0
758665-20-2 773032-42-1 775559-48-3
815585-11-6 815585-12-7 815585-14-9
815585-15-0 815585-16-1 815585-17-2
815585-18-3 815585-19-4 815585-20-7
815585-21-8 815585-22-9 815585-23-0
815585-24-1 815585-25-2 815585-26-3
815585-27-4 815585-28-5 815585-29-6

815585-30-9 815585-31-0 815585-32-1
815585-33-2 815585-34-3 815585-35-4
815585-36-5 815585-37-6 815585-38-7
815585-39-8 815585-40-1 815585-41-2
815585-42-3 815585-43-4 815585-44-5
815585-45-6 815585-46-7 815585-47-8
815585-48-9 815585-49-0 815585-50-3
815585-51-4 815585-52-5 815585-53-6
815585-54-7 815585-55-8 815585-56-9
815585-57-0 815585-58-1 815585-59-2
815585-60-5 815585-61-6 815585-62-7
815585-63-8 815585-64-9 815585-65-0
815585-66-1 815585-67-2 815585-68-3
815585-69-4 815585-70-7 815585-71-8
815585-72-9 815585-75-2 815585-76-3
815585-77-4 815585-78-5 815585-80-9
815585-81-0 815585-82-1 815585-83-2
815585-84-3 815585-85-4 815585-86-5
815585-87-6 815585-88-7 815585-89-8
815585-90-1 815585-91-2 815585-92-3
815585-93-4 815585-94-5 815585-95-6
815585-97-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral acylguanidine compds. and therapeutic use)

RN 1152-29-0 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-[(1,1-dimethylethyl)amino]- (CA INDEX NAME)



RN 1154-25-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]- (CA INDEX NAME)



RN 1161-94-0 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[imino(phenylamino)methyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 2038-35-9
CMF C12 H12 Cl N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



RN 1166-01-4 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[[[(3,4-dichlorophenyl)methyl]amino]iminomethyl]- (CA INDEX NAME)



RN 1428-95-1 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)



RN 2016-88-8 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-,

hydrochloride (1:1) (CA INDEX NAME)



RN 2038-35-9 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[imino(phenylamino)methyl]- (CA INDEX NAME)



RN 2088-58-6 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[[[(2,4-dichlorophenyl)methyl]amino]iminomethyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 2898-76-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[imino[(phenylmethyl)amino]methyl]- (CA INDEX NAME)



RN 3166-00-5 CAPLUS
CN Benzamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 27182-48-5 CAPLUS
CN Benzenepropanamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 41266-22-2 CAPLUS
CN Benzeneacetamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 60398-23-4 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-iodo- (CA INDEX NAME)



RN 90689-42-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[[[(2,4-dichlorophenyl)methyl]amino]iminomethyl]- (CA INDEX NAME)



RN 92660-58-7 CAPLUS

CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(dimethylamino)-, hydrochloride (1:?) (CA INDEX NAME)



RN 96861-65-3 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-[methyl(2-methylpropyl)amino]- (CA INDEX NAME)



RN 127105-63-9 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-5-[[2-[(aminoiminomethyl)amino]-2-oxoethyl]methylamino]-6-chloro- (CA INDEX NAME)



RN 161804-20-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[imino[(phenylmethyl)amino]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 183271-12-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 188754-46-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 196190-73-5 CAPLUS
CN 3-Quinolinecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 196190-77-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-6-methoxy- (CA INDEX NAME)



RN 230639-31-3 CAPLUS
CN Cyclopropanecarboxamide, N-(aminoiminomethyl)-2-phenyl-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 265322-51-8 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-bromophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 279241-29-1 CAPLUS
CN 1-Naphthalenecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 741654-11-5 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-fluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 747394-28-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-chlorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 749833-31-6 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-chlorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 756794-68-0 CAPLUS
CN [1,1'-Biphenyl]-4-carboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 758665-20-2 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-fluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 773032-42-1 CAPLUS
CN 2-Quinolinecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 775559-48-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[4-(dimethylamino)phenyl]-2-methyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-11-6 CAPLUS
CN 2,4-Pentadienamide, N-(aminoiminomethyl)-5-phenyl- (CA INDEX NAME)



RN 815585-12-7 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[3-(trifluoromethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-14-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-methylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-15-0 CAPLUS
CN Benzenepropanamide, N-[imino(phenylamino)methyl]- (CA INDEX NAME)



RN 815585-16-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-bromophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-17-2 CAPLUS
CN 2-Pyrazinecarboxamide, N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)-3-methoxy- (CA INDEX NAME)



RN 815585-18-3 CAPLUS

CN Benzenepropanamide, N,N'-(phenylcarbonimidoyl)bis- (9CI) (CA INDEX NAME)



RN 815585-19-4 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-bromophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-20-7 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(5-bromo-2-fluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-21-8 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-methylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-22-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,3-dimethylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-23-0 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(1-naphthalenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-24-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3,4-dichlorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-25-2 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,6-dichlorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-26-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-ethylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-27-4 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-chlorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-28-5 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,5-dimethylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-29-6 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[3-(1-methylethyl)phenyl]-, hydrochloride (1:?), (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-30-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[1,1'-biphenyl]-3-yl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-31-0 CAPLUS
CN 2,4-Pentadienamide, N-(aminoiminomethyl)-5-(3-bromophenyl)- (CA INDEX NAME)



RN 815585-32-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[3-(1-cyclohexen-1-yl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-33-2 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[3-(trifluoromethoxy)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-34-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[2-(trifluoromethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-35-4 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-ethoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-36-5 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[4-(trifluoromethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-37-6 CAPLUS

CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-38-7 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[2-(1,1-dimethylethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-39-8 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-methylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-40-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[1,1'-biphenyl]-2-yl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-41-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-hydroxy-N-[imino(phenylamino)methyl]- (CA INDEX NAME)



RN 815585-42-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[3-(1,1-dimethylethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-43-4 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3,4-difluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-44-5 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(5-bromo-2-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-45-6 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-ethoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-46-7 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(1,3-benzodioxol-5-yl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-47-8 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-48-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,3,5,6-tetramethylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-49-0 CAPLUS
CN 1-Naphthaleneacetamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 815585-50-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,3-difluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-51-4 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-methoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-52-5 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[4-(1-methylethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-53-6 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,4,6-trimethylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-54-7 CAPLUS
CN 2-Propenamide, N-[imino(phenylamino)methyl]-3-phenyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-55-8 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[2-(1-cyclohexen-1-yl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-56-9 CAPLUS
CN 2-Naphthaleneacetamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 815585-57-0 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-hydroxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-58-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[1,1'-biphenyl]-4-yl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-59-2 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-fluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-60-5 CAPLUS
CN 2-Propenamide, N,N'-(phenylcarbonimidoyl)bis[3-phenyl-, (2E,2'E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-61-6 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-furanyl)- (CA INDEX NAME)



RN 815585-62-7 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-nitrophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-63-8 CAPLUS
CN Benzamide, N-(aminoiminomethyl)-4-phenoxy- (CA INDEX NAME)



RN 815585-64-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[3-(1E)-1-hepten-1-ylphenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-65-0 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-cyclohexylphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-66-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-ethoxyphenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-67-2 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,4-dichlorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-68-3 CAPLUS

CN 2-Propenamide, N-(aminoiminomethyl)-3-phenyl-, hydrochloride (1:?), (2E)- (CA INDEX NAME)

Double bond geometry as shown.





RN 815585-69-4 CAPLUS
CN Acetamide, N-(aminoiminomethyl)-2-(4-chlorophenoxy)- (CA INDEX NAME)



RN 815585-70-7 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-[(4-fluorophenyl)amino]- (CA INDEX NAME)



RN 815585-71-8 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-nitrophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-72-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-furanyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-75-2 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-[4-(1,1-dimethylethyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-76-3 CAPLUS
CN Benzenepropanamide, N,N'-carbonimidoylbis- (9CI) (CA INDEX NAME)



RN 815585-77-4 CAPLUS
CN Benzamide, N-[imino[[(2E)-1-oxo-3-phenyl-2-propen-1-yl]amino]methyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-78-5 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-1-bromo- (CA INDEX NAME)



RN 815585-80-9 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3,4,5-trimethoxyphenyl)-, (2E)-
(CA INDEX NAME)

Double bond geometry as shown.



RN 815585-81-0 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(3-pyridinyl)- (CA INDEX NAME)



RN 815585-82-1 CAPLUS
CN 2,6-Naphthalenedicarboxamide, N2,N6-bis(aminoiminomethyl)- (CA INDEX
NAME)



RN 815585-83-2 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-6-bromo- (CA INDEX NAME)



RN 815585-84-3 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2-chloro-6-fluorophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-85-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-[imino(phenylamino)methyl]- (CA INDEX NAME)



RN 815585-86-5 CAPLUS
CN 2,4-Pentadienamide, N-(aminoiminomethyl)-5-(2-bromophenyl)- (CA INDEX NAME)



RN 815585-87-6 CAPLUS
CN 2-Pyrazinecarboxamide, 5-amino-N-(aminoiminomethyl)-6-chloro-3-methoxy- (CA INDEX NAME)



RN 815585-88-7 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-phenyl- (CA INDEX NAME)



RN 815585-89-8 CAPLUS
CN 2-Propenamide, N-[(dimethylamino)iminomethyl]-3-phenyl-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-90-1 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(4-nitrophenyl)-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-91-2 CAPLUS
CN 1-Naphthalenecarboxamide, N,N'-carbonimidoylbis- (9CI) (CA INDEX NAME)



RN 815585-92-3 CAPLUS
CN 2-Propenamide, 3-phenyl-N-[(phenylamino)(phenylimino)methyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 815585-93-4 CAPLUS
CN 2-Naphthalenecarboxamide, N,N'-carbonimidoylbis- (9CI) (CA INDEX NAME)



RN 815585-94-5 CAPLUS
CN 2-Pyrazinecarboxamide, N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)-3,4-dihydro-3-oxo- (CA INDEX NAME)



RN 815585-95-6 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(diethylamino)-, hydrochloride (1:?) (CA INDEX NAME)



x HCl

RN 815585-97-8 CAPLUS
CN 2-Naphthalenecarboxamide, N,N'-(phenylcarbonimidoyl)bis- (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:285287 CAPLUS Full-text
DOCUMENT NUMBER: 141:16940
TITLE: Interaction of amiloride and one of its derivatives with Vpu from HIV-1: a molecular dynamics simulation
AUTHOR(S): Lemaitre, V.; Ali, R.; Kim, C. G.; Watts, A.; Fischer, W. B.
CORPORATE SOURCE: Department of Biochemistry, Biomembrane Structure Unit, Oxford University, Oxford, OX1 3QU, UK
SOURCE: FEBS Letters (2004), 563(1-3), 75-81
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Vpu is an 81-residue membrane protein, with a single transmembrane segment that is encoded by HIV-1 and is involved in the enhancement of virion release via formation of an ion channel. Cyclohexamethylene amiloride (Hma) has been shown to inhibit ion channel activity. In the present 12-ns simulation study a putative binding site of Hma blockers in a pentameric model bundle built of parallel aligned helixes of the first 32 residues of Vpu was found near Ser-23. Hma orientates along the channel axis with its alkyl ring pointing inside the pore, which leads to a blockage of the pore.

IT 1428-95-1
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(interaction of amiloride and one of its derivs. with Vpu from HIV-1 in a mol. dynamics simulation)
RN 1428-95-1 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)
REFERENCE COUNT: 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:50990 CAPLUS Full-text
DOCUMENT NUMBER: 140:280823
TITLE: Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride
AUTHOR(S): Premkumar, A.; Wilson, L.; Ewart, G. D.; Gage, P. W.
CORPORATE SOURCE: John Curtin School of Medical Research, Australian National University, Canberra, ACT 2601, Australia
SOURCE: FEBS Letters (2004), 557(1-3), 99-103
CODEN: FEBLAL; ISSN: 0014-5793
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A 63 residue peptide, p7, encoded by hepatitis C virus was synthesized and tested for ion channel activity in lipid bilayer membranes. Ion channels formed by p7 had a variable conductance: some channels had conductances as low as 14 pS. The reversal potential of currents flowing through the channels formed by p7 showed that they were permeable to potassium and sodium ions and less permeable to calcium ions. Addition of Ca2+ to solns. made channels formed by p7 less potassium- or sodium-selective. Hexamethylene amiloride, a drug previously shown to block ion channels formed by Vpu encoded by HIV-1, blocked channels formed by p7. In view of the increasing number of peptides encoded by viruses that have been shown to form ion channels, it is suggested that ion channels may play an important role in the life cycle of many viruses and that drugs that block these channels may prove to be useful antiviral agents.

IT 1428-95-1, 5-(N,N-Hexamethylene)amiloride
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride)
RN 1428-95-1 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-(hexahydro-1H-azepin-1-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS RECORD (44 CITINGS)
REFERENCE COUNT: 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2003:610264 CAPLUS Full-text
DOCUMENT NUMBER: 139:143906
TITLE: Antiviral agents based on nitrogen heterocycles
INVENTOR(S): Anderson, David Andrew; Gazina, Elena Vladimirovna
PATENT ASSIGNEE(S): The MacFarlane Burnet Institute for Medical Research and Public Health Limited, Australia
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2003063869	A1	20030807	WO 2003-AU93		20030130 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2474821	A1	20030807	CA 2003-2474821		20030130 <--
EP 1480648	A1	20041201	EP 2003-700694		20030130 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1638772	A	20050713	CN 2003-804954		20030130 <--
JP 2005522425	T	20050728	JP 2003-563559		20030130 <--
AU 2003202298	B2	20070726	AU 2003-202298		20030130 <--
NZ 534292	A	20080926	NZ 2003-534292		20030130 <--
US 20050080122	A1	20050414	US 2004-503324		20041126 <--
PRIORITY APPLN. INFO.:			AU 2002-228	A	20020131 <--
			WO 2003-AU93	W	20030130 <--

OTHER SOURCE(S): MARPAT 139:143906

AB The present invention relates generally to compds. useful in the amelioration of symptoms associated with viral infection. More particularly, the present invention relates to the use of compds. which exhibit a physiol. effect on membranous and/or transmembrane structures on or in a cell and which directly or indirectly reduce or inhibit or otherwise prevent viral infection, processing and/or release from the cell. Even more particularly, the present invention contemplates the use of one or more compds. which modulate at least one host cell ion channel in the prophylaxis, treatment and/or symptomatic relief of viral infection in vertebrate animals and in particular in human subjects. The compds. may be provided alone or in combination with other compds. such as those which block or inhibit or at least impair ion channelling. A preferred embodiment of the present invention is the use of the aforementioned anti-viral compds. in the therapeutic management of

vertebrate animals including humans, to prevent, reduce or treat infection by certain species of the Picornaviridae family of viral pathogens such as but not limited to Rhinovirus or Enterovirus species. Representative viruses of the Rhinovirus and Enterovirus genera were chosen. The effectiveness of verapamil in inhibiting Rhinovirus 2 production in HeLa cells was demonstrated.

IT 1154-25-2, EIPA 2898-76-2, Benzamil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral agents based on nitrogen heterocycles)

RN 1154-25-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-chloro-5-[ethyl(1-methylethyl)amino]- (CA INDEX NAME)



RN 2898-76-2 CAPLUS
CN 2-Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-[imino[(phenylmethyl)amino]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:136991 CAPLUS Full-text
DOCUMENT NUMBER: 134:198075
TITLE: Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
INVENTOR(S): Patel, Mahesh V.; Chen, Feng-Jing
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 13
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001012155	A1	20010222	WO 2000-US18807	20000710 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6309663	B1	20011030	US 1999-375636	19990817 <--
CA 2380642	A1	20010222	CA 2000-2380642	20000710 <--
EP 1210063	A1	20020605	EP 2000-947184	20000710 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506476	T	20030218	JP 2001-516502	20000710 <--
NZ 517659	A	20041224	NZ 2000-517659	20000710 <--
AU 780877	B2	20050421	AU 2000-60838	20000710 <--
US 20010024658	A1	20010927	US 2000-751968	20001229 <--
US 6458383	B2	20021001		

PRIORITY APPLN. INFO.:
US 1999-375636 A 19990817 <--
WO 2000-US18807 W 20000710 <--

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the composition, or can be co-administered with the composition as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a composition containing Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

IT 2016-88-8, Amiloride hydrochloride
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

RN 2016-88-8 CAPLUS

CN 2-Pyrazinecarboxamide, 3,5-diamino-N-(aminoiminomethyl)-6-chloro-, hydrochloride (1:1) (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d his

     (FILE 'HOME' ENTERED AT 10:38:03 ON 04 AUG 2009)

     FILE 'REGISTRY' ENTERED AT 10:38:33 ON 04 AUG 2009
L1             STRUCTURE UPLOADED
L2          50 S SSS SAM L1
L3       60043 S SSS FULL L1
               SAVE L3 ACYLGUANIDIN/A

     FILE 'CAPLUS' ENTERED AT 10:41:42 ON 04 AUG 2009
               E US2005-562296/APPS
L4           1 S E3
               SEL RN L4

     FILE 'REGISTRY' ENTERED AT 10:43:11 ON 04 AUG 2009
L5         149 S E1-E149
L6         118 S L5 AND L3

     FILE 'CAPLUS' ENTERED AT 10:45:38 ON 04 AUG 2009
L7         835 S L6
L8         701 S L7 AND (AY<2005 OR PY<2005 OR PRY<2005)
L9           8 S L8 AND ANTIVIRAL

=> save temp l7 gage10562296/a
ANSWER SET L7 HAS BEEN SAVED AS 'GAGE10562296/A'

=> fil reg
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                  62.58     255.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                     ENTRY    SESSION
CA SUBSCRIBER PRICE                                  -6.56      -6.56

FILE 'REGISTRY' ENTERED AT 10:55:55 ON 04 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:    2 AUG 2009  HIGHEST RN 1171815-79-4
DICTIONARY FILE UPDATES:   2 AUG 2009  HIGHEST RN 1171815-79-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:
```

http://www.cas.org/support/stngen/stndoc/properties.html

```
=> s 183271-12-7/rn
L10          1 183271-12-7/RN

=> d scan

L10  1 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   2-Naphthalenecarboxamide, N-(aminoiminomethyl)-
MF   C12 H11 N3 O
CI   COM
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**


ALL ANSWERS HAVE BEEN SCANNED


=> s (183271-13-8, 183271-14-9, 196190-77-9, 57486-95-0)/rn
L11          0 (183271-13-8, 183271-14-9, 196190-77-9, 57486-95-0)/RN

=> s 183271-13-8/rn
L12          1 183271-13-8/RN

=> s 57486-95-0/rn
L13          1 57486-95-0/RN

=> s 183271-14-9/rn
L14          1 183271-14-9/RN

=> s 196190-77-9/rn
L15          1 196190-77-9/RN

=> s l10 or l12 or l13 or l14 or l15
L16          5 L10 OR L12 OR L13 OR L14 OR L15

=> d scan

L16  5 ANSWERS   REGISTRY  COPYRIGHT 2009 ACS on STN
IN   2-Naphthalenecarboxamide, N-(aminoiminomethyl)-6-methoxy-
MF   C13 H13 N3 O2
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4

L16 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-bromo-
MF C12 H10 Br N3 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Propenamide, N-(aminoiminomethyl)-3-(2,6-dichlorophenyl)-
MF C10 H9 Cl2 N3 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-methoxy-
MF C13 H13 N3 O2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L16 5 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-
MF C12 H11 N3 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> fil caplu

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	6.24	262.10

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.56

FILE 'CAPLUS' ENTERED AT 11:03:29 ON 04 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing

of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Aug 2009 VOL 151 ISS 6
FILE LAST UPDATED: 3 Aug 2009 (20090803/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

=> s l16
L17 7 L16

=> d ibib abs hitstr l17 1-7
THE ESTIMATED COST FOR THIS REQUEST IS 39.48 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N:y

L17 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2009:179576 CAPLUS Full-text
DOCUMENT NUMBER: 150:229646
TITLE: Hepatitis C antiviral compositions and methods
INVENTOR(S): Ewart, Gary Dinneen; Luscombe, Carolyn Anne; Miller, Michelle
PATENT ASSIGNEE(S): Biotrom Limited, Australia
SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018609	A1	20090212	WO 2008-AU1130	20080804

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: AU 2007-904154 A 20070803
OTHER SOURCE(S): MARPAT 150:229646
AB The present invention relates to novel compns. having anti-viral activity and in particular it relates to synergistic compns. active against Hepatitis C virus (HCV). The invention also relates to methods for retarding, reducing or otherwise inhibiting HCV growth and/or functional activity.
IT 183271-13-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(hepatitis C antiviral compns. and methods)
RN 183271-13-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-bromo- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:1356781 CAPLUS Full-text
DOCUMENT NUMBER: 146:100349
TITLE: Acylguanidines as antiviral compounds and their preparation, pharmaceutical compositions and use in the treatment of viral infections in mammals
INVENTOR(S): Ewart, Gary Dinneen; Best, Wayne Morris
PATENT ASSIGNEE(S): Biotron Limited, Australia
SOURCE: PCT Int. Appl., 49pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006135978	A1	20061228	WO 2006-AU880	20060623
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006261593	A1	20061228	AU 2006-261593	20060623

CA 2612403	A1	20061228	CA 2006-2612403		20060623
EP 1902017	A1	20080326	EP 2006-741271		20060623
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
JP 2008543886	T	20081204	JP 2008-517277		20060623
US 20090099239	A1	20090416	US 2007-922281		20071214
CN 101208297	A	20080625	CN 2006-80022641		20071224
IN 2008KN00290	A	20080926	IN 2008-KN290		20080121
KR 2008021810	A	20080307	KR 2008-701886		20080124
PRIORITY APPLN. INFO.:			AU 2005-903360	A	20050624
			WO 2006-AU880	W	20060623

OTHER SOURCE(S): CASREACT 146:100349; MARPAT 146:100349

GI



I II

AB The present invention relates to acylguanidine compds. of formula I and compns. having antiviral activity. Compds. of formula I wherein R1 is (un)substituted (un)fused cinnamyl, (un)substituted naphthyl, and (un)substituted phenyl; and their pharmaceutically acceptable salts thereof, are claimed. The invention also relates to methods for the therapeutic or prophylactic treatment of viral infections in mammals. Example compound II was prepared by olefination of 2,3-methylenedioxybenzaldehyde with tri-Et phosphonoacetate; the resulting Et 2,3-methylenedioxycinnamate underwent hydrolysis to give the corresponding cinnamic acid, which underwent amidation with guanidine to give compound II. All the invention compds. were evaluated for their antiviral activity, toxicity (TC50)and calcn. of the antiviral index (AI). From the assay it was determined that compound II exhibited an IC50 value 1.1 μM, TC50 of > 100 μM, and AI > 100.

IT 183271-13-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of acylguanidines as antiviral compds. and their use in treatment of viral infections in mammals)

RN 183271-13-8 CAPLUS

CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-bromo- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1156423 CAPLUS Full-text
DOCUMENT NUMBER: 142:86608
TITLE: Antiviral acylguanidine compounds, and their therapeutic use
INVENTOR(S): Gage, Peter William; Ewart, Gary Dinneen; Wilson, Lauren Elizabeth; Best, Wayne; Premkumar, Anita
PATENT ASSIGNEE(S): Biotron Limited, Australia
SOURCE: PCT Int. Appl., 215 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004112687	A2	20041229	WO 2004-AU866	20040626
WO 2004112687	A3	20070712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
AU 2004248859	A1	20041229	AU 2004-248859	20040626
CA 2529949	A1	20041229	CA 2004-2529949	20040626
EP 1646371	A2	20060419	EP 2004-737487	20040626
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004011900	A	20060919	BR 2004-11900	20040626
JP 2007508234	T	20070405	JP 2006-515560	20040626
ZA 2006000650	A	20070530	ZA 2006-650	20040626
NZ 544671	A	20090228	NZ 2004-544671	20040626
US 20070099968	A1	20070503	US 2005-562296	20051222
IN 2006KN00159	A	20070727	IN 2006-KN159	20060120
CN 101111475	A	20080123	CN 2004-80024097	20060222

PRIORITY APPLN. INFO.:		
AU 2003-903251	A	20030626
AU 2003-903850	A	20030725
AU 2003-904692	A	20030829
AU 2004-902902	A	20040531
WO 2004-AU866	W	20040626

OTHER SOURCE(S): MARPAT 142:86608

AB The invention discloses acylguanidine compds. having antiviral activity, as well as methods using these compds. to treat viral infections. Preparation of e.g. cinnamoylguanidine is included.

IT 183271-12-7 196190-77-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiviral acylguanidine compds. and therapeutic use)

RN 183271-12-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 196190-77-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-6-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

L17 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:442110 CAPLUS Full-text
DOCUMENT NUMBER: 133:68989
TITLE: Use of inhibitors of the sodium-hydrogen exchanger to alleviate age-related organ dysfunction and age-related diseases and to promote longevity
INVENTOR(S): Linz, Wolfgang; Lang, Hans-Jochen
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany
SOURCE: Ger. Offen., 147 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19859727	A1	20000629	DE 1998-19859727	19981223
CA 2357837	A1	20000706	CA 1999-2357837	19991208
WO 2000038661	A2	20000706	WO 1999-EP9621	19991208
WO 2000038661	A3	20001109		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1140056	A2	20011010	EP 1999-959387	19991208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 200101803	T2	20011022	TR 2001-1803	19991208
BR 9916505	A	20011120	BR 1999-16505	19991208

HU 2001004652	A2	20020328	HU 2001-4652		19991208
HU 2001004652	A3	20020930			
JP 2002533386	T	20021008	JP 2000-590615		19991208
AU 776761	B2	20040923	AU 2000-16576		19991208
RU 2238721	C2	20041027	RU 2001-120358		19991208
US 6420430	B1	20020716	US 1999-469299		19991222
MX 2001004956	A	20010731	MX 2001-4956		20010517
ZA 2001004301	A	20030220	ZA 2001-4301		20010525
HR 2001000470	A1	20020630	HR 2001-470		20010620
HR 2001000470	B1	20031031	HR 2001-47		20010620
NO 2001003145	A	20010822	NO 2001-3145		20010622
PRIORITY APPLN. INFO.:			DE 1998-19859727	A	19981223
			WO 1999-EP9621	W	19991208

AB Chronic alterations in function of vital organs during aging, e.g. losses in contractility of the heart and blood vessels and the occurrence of neoplasms, are ameliorated and the life span is prolonged by administration of cellular Na+-H+ exchange inhibitors such as benzoylguanidines and other acylguanidines, including cariporide. Thus, rats administered cariporide (0.3% in the feed) from the age of 1 mo showed a 30% increase in life span (to a maximum of 39 mo), decreases in heart and spleen weight, decreased connective tissue infiltration in the heart, less retinal atrophy, and less histol. damage to kidney tubules at age 30 mo than controls.

IT 183271-12-7D, derivs.
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of sodium-hydrogen exchanger inhibitors to alleviate age-related organ dysfunction and age-related diseases and to promote longevity)

RN 183271-12-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L17 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1997:590066 CAPLUS Full-text
DOCUMENT NUMBER:	127:257127
ORIGINAL REFERENCE NO.:	127:50081a,50084a
TITLE:	Structural requirements for potent Na/H exchange inhibitors obtained from quantitative structure-activity relationships monocyclic and bicyclic aroylguanidines
AUTHOR(S):	Yamamoto, Takeshi; Hori, Manabu; Watanabe, Ikuo; Tsutsui, Hisayoshi; Harada, Kengo; Ikeda, Shoji; Ohtaka, Hiroshi
CORPORATE SOURCE:	Product R and D Laboratory, Kanebo Ltd., Osaka, 534, Japan
SOURCE:	Chemical & Pharmaceutical Bulletin (1997), 45(8), 1282-1286 CODEN: CPBTAL; ISSN: 0009-2363
PUBLISHER:	Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal
LANGUAGE: English

AB The quant. structure-activity relationship (QSAR) of N-(3-amino-6-chloro-5-ethylisopropylaminopyrazine-4-carbonyl)guanidine (EIPA) 1ac and its derivs. as Na/H exchange inhibitors was analyzed using the steric parameters and an indicator variable. The results indicated that bicyclic aroylguanidines might have Na/H exchange inhibitory activity. Therefore, various bicyclic aroylguanidines were synthesized and tested for Na/H exchange inhibitory activity. The QSAR study of the bicyclic aroylguanidines showed that hydrophobic bicyclic rings seemed to be preferable for potent activity. The hydrophobicity of the aroyl ring moiety was thought to be particularly important. Thus, the QSAR of EIPA and its derivs. was re-analyzed using hydrophobicity and steric parameters. The results indicated that high hydrophobicity of the pseudo-ring moiety and a substituent of appropriate length at the position corresponding to the 5-position of the naphthalene ring enhance the activity. As expected from the results, 5-bromo-2-naphthoylguanidine 3b and 5-methoxy-2-naphthoylguanidine 3c exhibited strong activity. These findings will be helpful to design new, potent Na/H exchange inhibitors.

IT 183271-12-7 183271-13-8 183271-14-9
196190-77-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(structure-activity relationships monocyclic and bicyclic aroylguanidines as Na/H exchange inhibitors)

RN 183271-12-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 183271-13-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-bromo- (CA INDEX NAME)



RN 183271-14-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-methoxy- (CA INDEX NAME)



RN 196190-77-9 CAPLUS
CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-6-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L17 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1996:693764 CAPLUS Full-text
DOCUMENT NUMBER: 125:328314
ORIGINAL REFERENCE NO.: 125:61495a,61498a
TITLE: Preparation of Na+/H+ exchange-inhibiting naphthoylguanidines
INVENTOR(S): Hori, Manabu; Watanabe, Ikuo; Yamamoto, Takeshi; Ootaka, Hiroshi; Harada, Kengo; Maruo, Joji; Morita, Tominori
PATENT ASSIGNEE(S): Kanebo Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08225513	A	19960903	JP 1995-150924	19950524
PRIORITY APPLN. INFO.:			JP 1995-150924 A	19950524
			JP 1994-335952	19941221

OTHER SOURCE(S): MARPAT 125:328314
GI



I

AB The title compds. I (R = H, halo, alkoxy) or their salts are prepared Guanidine HCl salt (1.1 g) was treated with NaH and NaOMe in MeOH under reflux for 30 min and treated with 0.55 g 2-naphthoyl chloride in 1,2-dimethoxyethane at room temperature for 2 h to give 0.42 g I (R = H), which showed in vitro inhibition of Na propionate-induced blood platelet swelling with IC50 0.091 μM, vs. 13 μM, for amiloride.

IT 183271-13-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of Na+/H+ exchange-inhibiting naphthoylguanidines)

RN 183271-13-8 CAPLUS

CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-bromo- (CA INDEX NAME)



IT 183271-12-7P 183271-14-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of Na+/H+ exchange-inhibiting naphthoylguanidines)

RN 183271-12-7 CAPLUS

CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)- (CA INDEX NAME)



RN 183271-14-9 CAPLUS

CN 2-Naphthalenecarboxamide, N-(aminoiminomethyl)-5-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L17 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
CAPLUS Full-text
ORIGINAL REFERENCE NO.: 84:1967a,1970a
TITLE: Substituted phenylacetylguanidines, a new class of antihypertensive agents
AUTHOR(S): Bream, J. B.; Lauener, H.; Picard, C. W.; Scholtysik, G.; White, T. G.
CORPORATE SOURCE: Res. Inst. Wander, Bern, Switz.
SOURCE: Arzneimittel-Forschung (1975), 25(10), 1477-82
CODEN: ARZNAD; ISSN: 0004-4172
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 84:12322
GI For diagram(s), see printed CA Issue.
AB The synthesis of a new series of phenylacetylguanidines is described. Several of them exhibited high antihypertensive activity in the rat, the most potent member of the series being 2,6-dichlorophenylacetylguanidine-HCl (I) [29110-48-3]. Structure-activity studies suggested that for good antihypertensive activity the following features were essential: 2,6-dichloro substitution in the aromatic nucleus; an unbranched acetyl link between the aromatic and the guanidine groups. The activity was largely retained on lower alkylation or hydroxyalkylation of the amidine nitrogens but for optimal activity these should be unsubstituted.
IT 57486-95-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation and antihypertensive activity of)
RN 57486-95-0 CAPLUS
CN 2-Propenamide, N-(aminoiminomethyl)-3-(2,6-dichlorophenyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

STN INTERNATIONAL LOGOFF AT 11:04:41 ON 04 AUG 2009